What is the Prognosis of CIDP Neuropathy?
Looking at the Prognosis of CIDP Neuropathy
Prognosis of CIDP Neuropathy? The course of CIDP varies widely among individuals. Some may have a bout of CIDP followed by spontaneous recovery, while others may have many bouts with partial recovery in between relapses. The disease is a treatable cause of acquired neuropathy and initiation of early treatment to prevent loss of nerve axons is recommended. However, some individuals are left with some residual numbness or weakness.
The ideal treatment for preventing further loss of nerve axons is IVIG treatment. IVIg has been introduced as the main therapy for CIDP over the last two decades. Multiple well-controlled studies have demonstrated that approximately 50–70% of patients respond to IVIg [Hahn et al. 1996b; Mendell et al. 2001; Hughes et al. 2008]. Improvement occurs within a few weeks, and rarely recovery may be dramatic, appearing 1 or 2 days after completing the infusion. Usually the benefit is transient (1–6 weeks) with 50% of patients relapsing within weeks to months and subsequently requiring regular infusions to maintain maximum improvement. Patients with a progressive course or predominantly sensory deficits with tremor may be less likely to improve. Mendell and coworkers showed that 11 of 29 treatment-naïve patients with CIDP improved by one or more disability grades after receiving IVIg, 1.0 g/kg/day at baseline and after 3 weeks, compared with two of 21 patients who received placebo; 76% of IVIg-treated patients had improved strength [Mendell et al. 2001]. Improvement was noted as early as 10 days after therapy.